NovaBay Pharmaceuticals Inc (NBY)

[illflyifyoubuy]

Pre & post market hours trading.

That's what From T trades, are.

[Earlofsandwich]

any thoughts on trade sheet full of T FORM trades???is this dilution?

[TeddyCaswell]

Tomorrow

[alchemytrader]

I think it could have been but the overall market was crap and it couldnt gain any momentum.

[illflyifyoubuy]

It was, during the pre hours.

[Earlofsandwich]

sorry,that happen to you or anyone else 4 that matter, sure seems some stuff going on that shouldn't be, but not anything real new i guess, but sure not fair........

[kingBach]

This is gonna climb. If FDA approves test kit...Boom

[BeasTrader]

This should have been 1.20+ with this news

[alchemytrader]

Yeah cut losses .96

[BeasTrader]

I bet you regret that now

[kingBach]

Is the float here 16.9M

[alchemytrader]

scooped some 1.12 here

[stock1ace1]

In $1.12 Impressive update ! Read ~>

I’m gratified to report this parallel strategy is working very well, with combined product sales in the month of April surpassing our total revenue for the entire first quarter.

Just as Avenova is considered the highest quality product in its market segment, we are also confident in the quality of the new products we are securing for U.S. distribution in response to the COVID-19 pandemic. Our confidence is based on the reputation of our suppliers as well as the results from third-party lab testing.

We began selling KN95 masks through our website Avenova.com less than two months ago, and we are already nearing the milestone of one million units sold. These KN95 masks are effective in filtering out at least 95 percent of airborne particles, including microorganisms, dust, pollen and air pollution, making them ideal for personal protection in public places. We are highly confident in their design as they are CE certified and meet the KN95-level requirements. In order to distinguish them from the many inferior quality masks currently in the marketplace, our partner mask manufacturer has submitted the KN95 masks for emergency use authorization (“EUA”) from the U.S. FDA to further validate their quality. Due to the backlog of new COVID-19 related products submitted, the FDA has not given us a timeframe for review. While many Americans continue to have difficulty acquiring masks, our masks are in stock in the U.S. and ready for immediate shipping, with customers typically receiving them within a day or two of ordering.

[jaj-dan]

April revenues are greater than the entire first quarters revenues! That’s pretty good news.

https://www.businesswire.com/news/home/20200514005289/en/NovaBay-Pharmaceuticals-Issues-Letter-Stockholders

[Earlofsandwich]

that particular news still coming but earnings to @ least triple then another push up after that when test are surely approved.....go NBY smart 1's still loading...

[ninebix]

FDA News should be coming soon $$

[Earlofsandwich]

every day and or hour closer to positives results from these guys..go NBY....!

[Earlofsandwich]

need to lose their NBY shares,they have them on the block or creating one go,go,ground swell, got to start somewhere...

[Earlofsandwich]

NBY i see multi dollars, @ .93 cent???

[Earlofsandwich]

no slap thew ASK no get the shares...go NBY

[Earlofsandwich]

wake up NBY whom is selling this low????lets go 2.0

[Earlofsandwich]

I cont. to stack these NBY shares waiting 4 the value to jump.....GLTA.

[looking 4 a win]

Do you happen to have link?

[Look-See]

Won't they also tell us how their profits are doing?

[conquistidor]

Conference call today after hrs.
Should get update on covid 19 test.

[ClayTrader]

* * $NBY Video Chart 05-06-2020 * *

Link to Video - click here to watch the technical chart video

[ttottip]

Is the replacement of finance chief a good news or a bad one just before the Q report?

[ttottip]

1.20's today?

[jaj-dan]

NovaBay Pharmaceuticals Appoints Andrew D. Jones Chief Financial Officer

May 05, 2020 6:50 AM ETBusiness WireNovaBay Pharmaceuticals, Inc. (NBY)
EMERYVILLE, Calif.--(BUSINESS WIRE)-- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the appointment of Andrew D. Jones as Chief Financial Officer and Treasurer, effective May 1, 2020. Mr. Jones brings to NovaBay more than 20 years of finance and accounting experience primarily in the life sciences industry. He replaces Lynn Christopher, who assumed these positions on an interim basis in April 2020 and will consult to NovaBay to support a smooth transition.

“We are delighted to secure a well-qualified professional to fill our executive finance position on a permanent basis and to do so very quickly,” said Justin Hall, NovaBay CEO. “Andrew has served every critical function in finance and accounting from high-level strategic planning and financial modeling, budgeting and cash management, to technical accounting, audit and tax compliance, and managing daily accounting operations. The breadth of his finance and accounting experience, his background in the life sciences industry and relevant public company accounting expertise make him an excellent fit.”

“Serving as NovaBay’s CFO will allow me to use my entire skillset in an executive capacity in a dynamic environment,” said Mr. Jones. “I’m committed to working closely with the NovaBay team to ensure financial accountability and prudence, and to achieve our goals for growth and business success.”

Mr. Jones most recently served as an independent consultant, helping companies to meet their accounting and finance requirements. He previously served as Vice President, Finance of MyoScience, Inc., a commercial-stage medical device company, through its acquisition by Pacira BioSciences in August 2019. In this position, he was responsible for senior management and Board-level reporting, and overseeing all accounting and finance functions, including strategic planning and business development decisions that resulted in revenue growth and gross margin improvements. Before that, Mr. Jones was Senior Director of Finance and Controller of Armetheon, Inc., a late-stage drug development company, and Corporate Controller of Asante Solutions, Inc., a medical device company acquired by Bigfoot Biomedical, Inc., and Genelabs Technologies, Inc. (GNLB), a Nasdaq-listed company subsequently acquired by GlaxoSmithKline. Earlier in his career he was Transaction Services, Senior Manager at PricewaterhouseCoopers providing clients with M&A advisory services, and a Senior Associate at Price Waterhouse, LLP. Mr. Jones received a BA in business administration from the University of Washington.

[ttottip]

Ready to lift off ?

[ttottip]

Wow! More than 100,000 shares on the bid.

[stockmavin]

Has anybody been able to find the FDA filing? TIA

[ttottip]

This will explode!

[ttottip]

Let's start the run!

[Taurus69]

$nby $0.9437

[ttottip]

All technical indicators point to buy. Soon we'll see a run.

[looking 4 a win]

Some Jack azz shorter is pushing this down again.

[Taurus69]

$nby $.96

[ninebix]

NovaBay is doing it the right way

Public health experts say the FDA shouldn’t have waived its reviews of antibody tests and are calling on it to crack down

https://www.politico.com/amp/news/2020/04/27/reliable-antibody-tests-coronavirus-207589

[conquistidor]

Not true they have applied for an EUA thru fda. I believe they should know if approved within 2 weeks.

[moder]

made in china test kits takes a long wait for APPROVAL like AYTU

[looking 4 a win]

Gotcha, thanks

[stockmavin]

The contract was signed and waiting for FDA approval. The agreement is worthless without the approval.

[looking 4 a win]

Anybody wanna chime in on what’s happening? Can’t find any DD.

[Taurus69]

$nby $.9955

[kingsransome]

all in $$$$$$$$$ mhop

[traderjack1]

Ty

[stockmavin]

Not sure. Was not in the PR and could not find that information in my searches.

[jaj-dan]

So than how fast and at what quantities can they get the product from China?

[stockmavin]

They do not manufacture of produce. They are distributors for Shenzhen Microprofit Biotech who are the manufacturers in China. NovaBay seeks Emergency Use Authorization from the FDA.